Mainz Biomed BV
NASDAQ:MYNZ

Watchlist Manager
Mainz Biomed BV Logo
Mainz Biomed BV
NASDAQ:MYNZ
Watchlist
Price: 1.47 USD -2%
Market Cap: 5.6m USD

Net Margin
Mainz Biomed BV

-2 421.8%
Current
-2 604%
Average
-6.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 421.8%
=
Net Income
-21.7m
/
Revenue
894k

Net Margin Across Competitors

Mainz Biomed BV
Glance View

Market Cap
5.6m USD
Industry
Biotechnology

Mainz Biomed BV operates as a biotechnology company. The company is headquartered in Mainz, Hessen. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

MYNZ Intrinsic Value
0.55 USD
Overvaluation 63%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

Summary
MYNZ intrinsic value, competitors valuation, and company profile.
DCF Valuation
MYNZ stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MYNZ stock valuation using valuation multiples.
Wall Street Estimates
MYNZ price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MYNZ stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 421.8%
=
Net Income
-21.7m
/
Revenue
894k
What is the Net Margin of Mainz Biomed BV?

Based on Mainz Biomed BV's most recent financial statements, the company has Net Margin of -2 421.8%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 273,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.